| Document |
Document Title |
|
WO/2007/072092A2 |
The present invention relates to new phenanthridine derivatives of formula (I), wherein the variables are as defined in the specificition, to processes for producing the same, to pharmacological compositions containing the same and to th...
|
|
WO/2007/062002A2 |
A compound of Formula (I) wherein R1, R2, and R3 are independently at each occurrence hydrogen, a halogen, a cyano functionality, a C1-C20 aliphatic functionality, a C3-C10 cycloaliphatic functionality or a C3-C20 aromatic functionality,...
|
|
WO/2007/059008A2 |
N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also describe...
|
|
WO/2007/054292A2 |
Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful ...
|
|
WO/2007/051255A1 |
The present invention relates to a process for the preparation of compounds containing an azacyclic ring system, the process comprising reacting a ketone compound of the formula (I) with a compound of formula (II), and compounds prepared...
|
|
WO/2007/044475A1 |
The present teachings relate to the field of anti-inflammatory substances, and more particularly to the preparation of compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, the pres...
|
|
WO/2007/039884A1 |
Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided are processes for preparing comp...
|
|
WO/2007/038459A2 |
The invention relates to the use of carboxyamine compounds and salts thereof in the treatment of HDAC dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.
|
|
WO/2007/030939A2 |
Disclosed are compounds and pharmaceutically acceptable compositions thereof which modulate the interaction between nerve growth factor and precursors thereof and neurotrophm receptors and treat disease conditions mediated therefrom such...
|
|
WO/2007/030940A2 |
Disclosed are compounds and pharmaceutically acceptable compositions thereof which modulate the interaction between nerve growth factor and precursors thereof and neurotrophm receptors and treat disease conditions mediated therefrom such...
|
|
WO/2007/028337A1 |
A process for preparing optically active clopidogrel and its analogues methyl tetrahydrothienopyridine acetate of formula (XII), uses halophenylacetonitrile (VIII) as starting material, tetrahydrothienopyridine acetonitrile (IV) and tetr...
|
|
WO/2007/028638A1 |
The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1, R2, Q1-Q3, and Z are defined as set forth in the specification. The invention is also...
|
|
WO/2007/027719A2 |
The present invention provides analogs of formula (I) of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and ora...
|
|
WO/2007/025534A1 |
The invention relates to new fredericamycin derivatives, to pharmaceuticals comprising them or their salts, and to the use of the fredericamycin derivatives for treating disorders, especially tumoral disorders.
|
|
WO/2007/019752A1 |
The present invention provided a process for the preparation of gabapentin hydrochloride. The process comprises: conventing 1,5-dicyano-2,4-dioxo-3-azaspiro[5,5]undecane into 1,5-dicarbamoyl-2,4-dioxo-3-azaspiro[5,5]undecane at a tempera...
|
|
WO/2007/019942A1 |
The invention relates to a novel metal complex. Compounds of this type can be used as functional materials in a series of different applications that can be attributed in the largest sense to the electronics industry.
|
|
WO/2007/020636A1 |
The present invention provides compounds of the general formula I, and uses thereof for printing electronic components such as wires, resistors and LEDs.
|
|
WO/2007/018168A1 |
It is intended to provide a compound which can be used for preventing and/or treating a disease associated with 5HT2B receptor and 5HT7 receptor, particularly for treating irritable bowel syndrome (IBS) and/or preventing migraine. It was...
|
|
WO/2007/014902A2 |
The invention relates to multiple chromophores with a rylene base of general formula (I), where the variables have the following meanings: rylene is a group of formula (A), functionalised with at least one imide, ester, or amide group op...
|
|
WO/2007/016029A2 |
The present invention relates to methods for synthesizing compounds useful as 5HT2C agonists or partial agonists, derivatives thereof, and to intermediates thereto.
|
|
WO/2007/014137A2 |
8-Substituted-2,6-methano-3-benzazocines of general structure; formula (I) are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti- addiction medications. One embodiment is the subgenus of biphenylethyl co...
|
|
WO/2007/002258A2 |
The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyros...
|
|
WO/2007/000464A1 |
This invention relates to novel 3-aza-spiro[5.5]undec-8-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharma...
|
|
WO/2007/002254A2 |
The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosin...
|
|
WO/2007/000465A1 |
This invention relates to novel 3-aza-spiro[5.5]undecane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceu...
|
|
WO/2006/136063A1 |
The present invention discloses a new type of aporphine or secoaporphine compounds, a process for producing the same, and a pharmaceutical composition comprising the said compound which is used for preventing or treating diabetes. The sa...
|
|
WO/2006/133805A1 |
Compounds of formula I in which s, k, I, W, R1, R2, R3 and U have the meanings given in claim 1 can be used, inter alia, for the treatment of tumors.
|
|
WO/2006/133821A1 |
The invention relates to compounds of formula (i), wherein W, R, R1, R2, R3, R4, R5, R6 and R7 have meanings given in claim 1 and can be used for treating tumors.
|
|
WO/2006/132192A1 |
A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof which has a therapeutic or prophylactic effect on an SNS-related disease such as neuropathic pain. (1) wherein R1 and R2 independently represent an a...
|
|
WO/2006/130416A2 |
The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.
|
|
WO/2006/129679A1 |
The invention is directed to a CXCR3 antagonist comprising a compound represented by the general formula (I) (wherein all the symbols have the same meaning as defined in the description), a salt thereof, a quaternary ammonium salt thereo...
|
|
WO/2006/125812A1 |
This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine r...
|
|
WO/2006/117383A1 |
Rylene derivatives are disclosed having the general formula (I), in which the variables have the meanings indicated in the claims. These compounds are used as pigments and I.R. dyes.
|
|
WO/2006/116311A2 |
Opioid receptor agonist compounds and the their use in treatment of pain.
|
|
WO/2006/111511A1 |
The invention relates to rylenetetracarboxylic acid diimides of general formula (I) wherein the variables have the following designations: R represents radicals that are the same or different and selected from hydrogen, preferably substi...
|
|
WO/2006/103511A1 |
6,7-Dihydro-5H-cyclopenta[b]pyridine and 5,6,7,8-tetrahydroquinoline compounds of Formula (I), including salts, hydrates and solvates thereof, that act as 5-HT2 receptor ligands and their uses in the treatment of diseases linked to the a...
|
|
WO/2006/105289A1 |
Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.
|
|
WO/2006/104141A1 |
A compound represented by the formula: (I) wherein Acyl represents an acyl group which can be used in the field of β-lactams; T represents S, SO or O; the group represented by the formula: (Q) represents a heterocyclic group which may b...
|
|
WO/2006/098855A2 |
The present invention is directed to processes for the synthesis of morphinans. In particular, a process for cyclizing a ß,γ-bicyclic ketone compound to form a nordihydrothebainone product using the Grewe cyclization reaction is improv...
|
|
WO/2006/096358A1 |
Compounds of the formula I or a pharmaceutically acceptable salt thereof: processes for their preparation, pharmaceutical compositions which contain them and their uses in therapy.
|
|
WO/2006/095009A1 |
Compounds of a certain formula (I), in which R1, R2, R3, R31, R4, R5, R51, R6 and R7 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
|
|
WO/2006/093666A2 |
The present invention relates to Isoquinoline Compounds, compositions comprising an effective amount of an Isoquinoline Compound, and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes, a diabetic ...
|
|
WO/2006/093677A1 |
The present invention relates to Tetracyclic Sulfonamide Compounds, compositions comprising an effective amount of a Tetracyclic Sulfonamide Compound and methods for treating or preventing an inflammatory disease, a reperfusion injury, d...
|
|
WO/2006/093667A1 |
The present invention relates to Tetracyclic Amino Compounds and Tetracyclic Carboxamido Compounds, compositions comprising an effective amount of a Tetracyclic Amino Compound or a Tetracyclic Carboxamido Compound and methods for treatin...
|
|
WO/2006/088080A1 |
Disclosed is a novel cyclohepta[b]pyridine-3-carbonylguanidine derivative having an inhibitory effect on pharmaceutical products, in particular on Na+/H+ exchangers (NHE). Also disclosed is a pharmaceutical product containing such a cycl...
|
|
WO/2006/086921A1 |
The present invention discloses a process for the preparation of clopidogrel. The process of the present invention uses nitrilase hydrolyze the racemic organic prussiate into corresponding organic acids having high optical rotation, and ...
|
|
WO/2006/069775A1 |
The invention relates to compounds of structure (I) having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of p...
|
|
WO/2006/072039A1 |
Nepetalactams and N-substituted derivatives thereof are prepared by alkylation of metallated lactams. Nepetalactams and N-substituted derivatives thereof have utility as insect repellents.
|
|
WO/2006/072037A1 |
Dihydronepetalactams and N-substituted derivatives thereof are prepared by alkylation of metallated lactams. Dihydronepetalactams and N-substituted derivatives thereof have utility as insect repellents.
|
|
WO/2006/065686A2 |
The present invention is concerned with certain novel spiro substituted heterocyclic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenase. They ...
|
